Digital Diagnostics Market Poised for Explosive Growth | Here's Why

March 28, 2024 06:04 PM AEDT | By EIN Presswire
 Digital Diagnostics Market Poised for Explosive Growth | Here's Why
Image source: EIN Presswire

JERSEY, NJ, US, March 28, 2024 /EINPresswire.com/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Digital Diagnostics Market Size, Share & Trends Analysis Report By Application (Cardiology, Oncology, Neurology, Pathology), End-User (Hospitals, Clinical Laboratories), And Product (Hardware And Software), Region, Market Outlook And Industry Analysis 2031"

The Global Digital Diagnostics Market is estimated to reach over USD 6.32 billion by 2031, exhibiting a CAGR of 18.48% during the forecast period.

Digital technologies are applied to healthcare diagnostics to change the way diseases are identified, tracked, and treated. This process is known as digital diagnostics. Digital diagnostics offer a more accurate and practical approach to healthcare diagnostics, lowering mistakes, improving accuracy, and enabling early treatments by utilizing data analytics, Al algorithms, and remote patient monitoring.

Digital diagnostics has the potential to enhance test accessibility by overcoming limitations associated with operating hours and personnel availability, which are factors that impede traditional diagnostics. It can also increase access to diagnostics in low-resource settings, which is more prevalent in high-income, middle-income, and low-income countries, where inadequate infrastructure and medical personnel pose an additional obstacle. Patients may acquire access to superior health information, develop the ability to self-manage their health, ensure adherence to medical treatment, and embrace healthier lifestyles by utilizing digital diagnostics.

The growing use of digital health technologies, growing healthcare expenditures, and the demand for precise and readily available diagnostic solutions are all expected to propel the digital diagnostics market's rise in the upcoming years. Long-standing competitors and recent arrivals can benefit significantly from this market's chances to take advantage of the rising need for cutting-edge diagnostic technology.


Download Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2372


Recent Developments:

• In Feb 2024, Roche disclosed that it had signed an arrangement with PathAI. PathAI will collaborate exclusively with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics market, according to the conditions of the agreement. RTD will collaborate exclusively with PathAI for a set period as the sole external algorithm development business for AI-powered companion diagnostics while keeping the opportunity to create its own algorithms for companion diagnostics. PathAI will retain the freedom to develop algorithms outside of companion diagnostics.

• In May 2022: In its most recent round of funding, the MedTech startup TestCard raised $10 million, which it will broadly use to expand the market for its current product line and introduce new offerings, including flu, pregnancy, CKD, and diabetes tests.

• In February 2022: In order to enable customers to request tests and potentially collect samples from home, Labcorp introduced Labcorp OnDemand, an online platform. The best diagnostic tests will be more easily accessible to people due to this platform.

List of Prominent Players in the Digital Diagnostics Market:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• GE Healthcare
• Siemens Healthineers
• Medtronic plc
• Nano-X Imaging Ltd.
• Koninklijke Philips N.V.
• Digital Diagnostics Inc.
• Riverain Technologies
• VUNO, Inc.
• AliveCor, Inc.
• Behold.ai.
• Brainomix
• Healthy.io
• Canon Inc.


Order the Full Report @ https://www.insightaceanalytic.com/buy-report/2372


Market Dynamics:

Drivers-

Heart disease, diabetes, and cancer are typical chronic illnesses that cause substantial concerns for the world's healthcare systems. Using digital diagnostics to treat chronic diseases has several benefits. Wearable technology, at-home testing, and remote monitoring can assist with early detection, enabling earlier intervention and reducing the disease burden. Furthermore, electronic diagnostics provide ongoing patient health data monitoring, allowing for more effective sickness treatment and customized drug adjustments.

Challenges:

One major issue is that patients and healthcare professionals need to be made aware of digital diagnostics. Digital diagnostic technology may not be widely used since a number of healthcare professionals may not be aware of its potential and advantages. Similarly, patients might not be aware of the benefits and accessibility of the tools. This ignorance could hinder the use of digital diagnostics and restrict the growth of the sector.

Regional Trends:

The North American digital diagnostics market is expected to register a significant market share in revenue and is projected to develop at a high CAGR soon. The expanding use of cutting-edge technologies, rising investments from both public and private entities, and rising product launches and initiatives by significant market players are all factors contributing to the expansion of the market in the region. For instance, PathAI announced the release of its AISightTM digital pathology image management system (IMS) for pathology laboratories in August 2023. This will additionally offer effective, comprehensive digital pathology workflows. Besides, Asia Pacific had a substantial share of the market. The rising prices of computer-aided diagnostics in the Asia-Pacific healthcare region are among the causes driving this growth. Growing awareness of these technologies' advantages contributes to developing the digital diagnostics market in Asia-Pacific.


Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2372

Segmentation of Digital Diagnostics Market-

By Product-
• Hardware
• Software

By Application-
• Cardiology
• Oncology
• Neurology
• Pathology
• Others

By End-User-
• Hospitals
• Clinical Laboratories
• Others

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Priyanka Tilekar
Insightace Analytic Pvt. Ltd.
+91 9420858007
email us here


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.